MBX Biosciences is trading at $60.30 (-4.29%) as broader markets decline amid rising geopolitical risk, oil prices, and hawkish Federal Reserve expectations.
- U.S. forces struck Iranian rocket launchers on August 30, while Brent crude rose more than 3.8% toward $91 per barrel, weighing on risk assets.
- No fresh company-specific catalyst was identified; MBX Biosciences’ latest major update was first-patient dosing in its Phase 3 trial on August 27.